We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Reneo Pharmaceuticals Inc (RPHM) USD0.0001

Sell:$6.93 Buy:$7.63 Change: $0.65 (8.25%)
Market closed |  Prices as at close on 25 January 2022 | Switch to live prices |
Change: $0.65 (8.25%)
Market closed |  Prices as at close on 25 January 2022 | Switch to live prices |
Change: $0.65 (8.25%)
Market closed |  Prices as at close on 25 January 2022 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Reneo Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the developing therapies for patients with rare genetic mitochondrial diseases. The Company is engaged in developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the source of energy for cellular processes. REN001 is a selective peroxisome proliferator-activated receptor delta (PPARd) agonist that has been shown to transcription of genes involved in mitochondrial function and fatty acid oxidation (FAO). The Company is developing REN001 in the three rare genetic diseases that present with myopathy and have unmet medical need: primary mitochondrial myopathies (PMM), long-chain fatty acid oxidation disorders (LC-FAOD), and glycogen storage disease type V (McArdle disease). The Company has completed Phase I b clinical trial in patients with PMM to REN001. It is conducting open-label Phase I b clinical trials of REN001 with LC-FAOD and with McArdle disease.

Contact details

18575 Jamboree Road, Suite 275-S
United States
+1 (858) 2830280

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$195.64 million
Shares in issue:
24.42 million
United States
US dollar

Key personnel

  • Mike Grey
    Executive Chairman of the Board, Founder
  • Gregory Flesher
    President, Chief Executive Officer, Director
  • Niall O'donnell
    Co-Founder, Director
  • Vinny Jindal
    Chief Financial Officer
  • Lynn Purkins
    Vice President of Clinical Operations
  • Alejandro Dorenbaum
    Chief Medical Officer
  • Ashley Hall
    Chief Development Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.